I'm LongbridgeAI, I can summarize articles.Star Sports Medicine Co. Ltd. performed exceptionally well in its initial public offering (IPO), with its stock price tripling at the start of trading and ultimately rising 132% at midday. The company sold 8.42 million shares at HKD 98.50 each, raising a net income of HKD 758 million (USD 97 million). The public offering for local Hong Kong investors was oversubscribed more than 7,800 times, while the international offering was oversubscribed 9.4 times. Star Sports Medicine is the fourth largest supplier of sports medicine implants and equipment in China, expected to hold approximately 6.5% market share in 2024
Shares of medical device company Star Sports Medicine Co. Ltd. (1609.HK) tripled from their IPO price when trading began on Tuesday, before giving back some of the gains to close up 132% at the midday break.
The company sold 8.42 million shares for HK$98.50 each, raising net proceeds of HK$758 million ($97 million). The public offering for local Hong Kong investors was more than 7,800 times oversubscribed, while the international offering was oversubscribed by 9.4 times.
Star Sports Medicine is China’s fourth-largest provider of sports medicine implants and devices, controlling about 6.5% of the market in 2024. The company’s revenue reached 403 million yuan ($59 million) last year, up 23% year-on-year, while its profit jumped 44% to 137 million yuan.
The company plans to use 30% of the IPO proceeds to expand its production capabilities and efficiency. Another 35% will go to R&D, 25% to commercialization, sales, and marketing, and the remaining 10% to general working capital.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here